This event has ended. Showing historical data.

FDA approves AstraZeneca's Camizestrant?
$1.06K
1
1
FDA approves AstraZeneca's Camizestrant?

$1.06K
1
1
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
As of market creation, the FDA's expected decision date for the specified application is April 30, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for AstraZeneca's Camizestrant as a treatment for HR+/HER2- advanced or metastatic breast cancer with ESR1 mutation by May 14, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a Ne
AI-generated analysis based on market data. Not financial advice.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
